06/01/23 7:00 AMNasdaq : BTAI conferenceslow floatBioXcel Therapeutics to Participate at Two Upcoming Investor ConferencesBioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcelRHEA-AIneutral
05/25/23 7:00 AMNasdaq : BTAI clinical triallow floatBioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or SchizophreniaClinically meaningful efficacy results observed with half (60mcg) of the approved dose of IGALMI™ Greater than 50% PEC response rate attained; proportionally consistent with dose response when compared to rates seen in SERENITY I and II BXCL501 was well tolerated and demonstrated favorable safetyRHEA-AIneutral
05/16/23 7:00 AMNasdaq : BTAI clinical triallow floatBioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MDD) ProgramBXCL501 was well tolerated across a broad dose range from 30mcg to 140mcg administered chronically Planning Phase 2 human proof-of-concept study to evaluate BXCL501 as a potential adjunctive treatment in MDD Data further supportive of ongoing clinical programs evaluating BXCL501 for potentialRHEA-AIneutral
05/08/23 7:00 AMNasdaq : BTAI earningslow floatBioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational HighlightsIGALMI™ (dexmedetomidine) commercial momentum accelerating with doubling of formulary wins, unlocking more than $55 million in targeted market opportunity, and an additional $255 million scheduled to vote Top-line data from pivotal SERENITY III Phase 3 trial (Part 1) for BXCL501 in bipolar orRHEA-AInegative
05/02/23 7:00 AMNasdaq : BTAI conferenceslow floatBioXcel Therapeutics to Present at the BofA Securities 2023 Health Care ConferenceBioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcelRHEA-AIneutral
04/24/23 7:00 AMNasdaq : BTAI conferencesearningslow floatBioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its first quarterRHEA-AIneutral
03/14/23 4:15 PMNasdaq : BTAI IPOofferinglow floatOnkosXcel Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public OfferingOnkosXcel Therapeutics, LLC (“OnkosXcel”) today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offeringRHEA-AIneutral
03/09/23 7:00 AMNasdaq : BTAI earningslow floatBioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational HighlightsIGALMI™ (dexmedetomidine) commercial execution fully underway in 2023 with key focus on market access and demand generation through expanded field team Multiple pivotal data readouts for BXCL501 expected in Q2 2023 in disease areas with 139 million agitation episodes, 1- 3 * includingRHEA-AIneutral
02/23/23 7:00 AMNasdaq : BTAI conferencesearningslow floatBioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarterRHEA-AIneutral
02/21/23 7:00 AMNasdaq : BTAI low floatBioXcel Therapeutics to Ring Nasdaq Stock Market Closing Bell TodayBioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcelRHEA-AIpositive